home / stock / eton / eton quote
Last: | $3.19 |
---|---|
Change Percent: | -0.98% |
Open: | $3.09 |
Close: | $3.19 |
High: | $3.2 |
Low: | $3.04 |
Volume: | 33,789 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.19 | $3.09 | $3.19 | $3.2 | $3.04 | 33,789 | 04-19-2024 |
$3.06 | $3.11 | $3.06 | $3.2 | $3.06 | 68,832 | 04-18-2024 |
$3.14 | $3.19 | $3.14 | $3.22 | $3.03 | 94,860 | 04-17-2024 |
$3.19 | $3.21 | $3.19 | $3.2472 | $3.11 | 29,822 | 04-16-2024 |
$3.22 | $3.38 | $3.22 | $3.4335 | $3.22 | 90,153 | 04-15-2024 |
$3.42 | $3.47 | $3.42 | $3.47 | $3.35 | 32,341 | 04-12-2024 |
$3.44 | $3.47 | $3.44 | $3.58 | $3.4 | 63,904 | 04-11-2024 |
$3.43 | $3.5 | $3.43 | $3.6711 | $3.41 | 50,734 | 04-10-2024 |
$3.57 | $3.48 | $3.57 | $3.755 | $3.43 | 67,309 | 04-09-2024 |
$3.45 | $3.54 | $3.45 | $3.5637 | $3.43 | 73,924 | 04-08-2024 |
$3.59 | $3.57 | $3.59 | $3.7 | $3.57 | 49,031 | 04-05-2024 |
$3.56 | $3.59 | $3.56 | $3.7627 | $3.52 | 37,229 | 04-04-2024 |
$3.6 | $3.6201 | $3.6 | $3.6999 | $3.51 | 46,770 | 04-03-2024 |
$3.68 | $4.1 | $3.68 | $4.1 | $3.56 | 123,044 | 04-02-2024 |
$3.75 | $3.85 | $3.75 | $3.85 | $3.6901 | 52,671 | 04-01-2024 |
$3.75 | $3.81 | $3.75 | $3.875 | $3.7 | 56,026 | 03-29-2024 |
$3.75 | $3.81 | $3.75 | $3.875 | $3.7 | 56,026 | 03-28-2024 |
$3.8 | $3.84 | $3.8 | $3.875 | $3.71 | 34,823 | 03-27-2024 |
$3.81 | $3.88 | $3.81 | $3.88 | $3.68 | 72,774 | 03-26-2024 |
$3.88 | $3.92 | $3.88 | $3.99 | $3.81 | 55,854 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU"...
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 Announce...